Akebia Therapeutics
May 12, 2014

Akebia to Present at the Annual UBS Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease, today announced that John P. Butler, President and Chief Executive Officer, will present at the annual UBS Global Healthcare Conference on Monday, May 19, at 2:30 p.m. Eastern Time. The conference will take place at The Sheraton Hotel in New York City.

A live audio webcast of the presentation will be available on the Company's website at http://ir.akebia.com/events.cfm. An archived presentation will be available for 90 days.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease. Akebia's lead product candidate, AKB-6548, is in a Phase 2b clinical trial in patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. AKB-6548 is being developed as a once-daily, oral therapy to inhibit hypoxia-inducible factor prolyl hydroxylase, which is expected to stabilize and increase levels of HIFα and improve the production of hemoglobin and red blood cells.

Source: Akebia Therapeutics, Inc.

Investors:
Argot Partners, LLC
David Pitts, +1-212-600-1902
david@argotpartners.com
or
Susan Kim, +1-212-203-4433
susan@argotpartners.com
or
Media:
Feinstein Kean Healthcare
Liz Falcone, +1-617-761-6727
liz.falcone@fkhealth.com

Source: Akebia Therapeutics, Inc.

News Provided by Acquire Media